Rachel Freedman commented on targeted treatments – those that attack a specific
characteristic of a cancer strain – becoming the norm in breast cancer care.
Dr. Eric Winer served as chair for a panel that developed the second international guidelines for management of advanced breast cancer.
Dr. Toni Choueiri led a study that found patients with non–clear cell renal cell carcinoma, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Tags: BreastCancer, Radiation
Dr. Harold Burstein commented on a study that found there was no evidence that surgery lowered the risk of death compared to more conservative lumpectomy and radiation.
Shannon Harrington, PhD, participated in a study showing a patient's race and ethnicity dramatically influenced their preferences about the care they receive at the end of their lives.
A clinical trial led by Dr. Ursula Matulonis and Dr. Joyce Liu showed a two-drug combination can signficantly improve benefit for women with ovarian cancer that has recurred after initial treatment.
Dr. William Kaelin commented on the cancer-stem-cell model, and the possibility of controlling cancer without killing it.
Rafael Irizarry, PhD, co-led a new study investigating all stages and types of cancers that appear to share a telltale signature of widespread changes to the epigenome.
Tags: BasicResearch, Genomics
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: